Given the established roles of other PLC isoforms in breast cancer progression, understanding the contribution of PLCH1 to tumor biology may provide novel insights into its potential as a therapeutic target, particularly in aggressive subtypes with poor prognoses. The gene discussed is HSPG2; the disease is neoplasm.